Literature DB >> 27357608

Reciprocal regulation of long noncoding RNAs THBS4‑003 and THBS4 control migration and invasion in prostate cancer cell lines.

Jinliang Liu1, Gong Cheng1, Haiwei Yang1, Xiaheng Deng1, Chao Qin1, Lixin Hua1, Changjun Yin1.   

Abstract

Increasing evidence implicates long noncoding RNAs (lncRNAs), a class of noncoding RNAs >200 nucleotides in length, in the development of cancer. However, the mechanism underlying the effects of lncRNAs in prostate cancer (PCa) remains to be elucidated. The present study aimed to investigate the role of lncRNA‑THBS4‑003 in the pathogensis of PCa. In the present study, a microarray containing 8,277 lncRNA probes and 32,207 mRNA probes were used to identify dysregulated mRNAs in three patients with PCa, and reverse transcription‑quantitative polymerase chain reaction was used to determine the expression levels of thrombospondin 4 (THBS4) and lncRNA‑THBS4‑003 in 46 primary PCa and adjacent non‑tumor tissue samples. The expression levels of THBS4 were determined in six samples of PCa and adjacent non‑tumor tissues using Western blot analysis. The effects of forced THBS4 knockdown and lncRNA‑THBS4‑003 knockdown in the two PCa cell lines, DU145 and PC‑3, were evaluated using cell migration and invasion assays, as well as using Western blot analysis. Of the 40,484 probes in the microarray, 354 were significantly upregulated (P<0.05; fold‑change >2). The most significantly upregulated mRNA was THBS4. The expression levels of THBS4 and lncRNA‑THBS4‑003 in the 46 primary PCa samples was significantly higher, compared with that in the adjacent non‑tumor tissue samples. Patients with Gleason scores >7 exhibited higher expression levels of lncRNA‑THBS4‑003, compared with patients with lower scores. Knockdown of THBS4 or lncRNA‑THBS4‑003 significantly reduced the migratory and invasive abilities of the PCa cells in vitro, and decreased the expression levels of p38 and matrix metalloproteinase (MMP)‑9. These findings suggested that the reciprocal regulation of lncRNA‑THBS4‑003 and THBS4 contributed to the pathogenesis of PCa. Therefore silencing lncRNA‑THBS4‑003 or THBS4 may inhibit PCa cell migration and invasion, and regulate the levels of MMP‑9 through the mitogen‑activated protein kinase signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27357608      PMCID: PMC4940078          DOI: 10.3892/mmr.2016.5443

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


Introduction

Prostate cancer (PCa) is one of the most frequently diagnosed malignancies in men worldwide (1). The incidence of PCa in China has increased (2,3), however, the mechanisms underlying the development and progression of PCa remain to be fully elucidated. Disease relapse and metastasis, as well as the development of hormone-refractory disease, remain the leading causes of mortality. Therefore, investigating the molecular mechanisms involved in the progression of PCa is of major importance and may reveal novel approaches for targeted PCa therapy. With the advent of tiling-resolution genomic microarrays and whole-genome and transcriptome sequencing technologies, studies have revealed that at least 90% of the genome is actively transcribed (4,5). Several of these transcripts have emerged as critical regulators of gene expression and determination of cell fate. A recently identified group of transcripts, termed long noncoding RNAs (lncRNAs), may contribute to a significant quantity of non-coding RNA which makes up the human transcriptome (6,7). lncRNAs are a class of noncoding RNAs >200 nucleotides in length; they can be transcribed by RNA polymerase (Pol) II/Pol I, and a number are transcribed by RNA Pol III. lncRNAs are involved in several biological processes, including X chromosome inactivation, nuclear structure, genomic imprinting and development (8,9). lncRNA dysfunction has been associated with cell fate determination and the pathogenesis of human disease, including cancer (10). Furthermore, several dysregulated lncRNAs are associated with the carcinogenesis and growth of tumors, including breast cancer, colon cancer, PCa, hepatocellular carcinoma and leukemia (11–15). lncRNA-thrombospondin 4 (THBS4)-003 is a processed transcript, which does not encode a protein product and has a length of 558 bp, which is >200 bp and, thus fits well within the definition for lncRNAs. lncRNA-THBS4-003 is located at chromosome 5p14.1 and partially overlaps with the protein-coding gene, THBS4 (16). Mitogen-activated protein kinases (MAPKs) are a family of kinases, which comprise one of the major signaling pathways involved throughout the development of PCa. MAPKs can be divided into three subfamilies: The extracellular-signal-regulated kinases, the c-Jun N-terminal kinases, and p38 MAPK. It is well known that p38 MAPK is capable of regulating several cellular responses to cytokines and stress; however, previous data demonstrated that p38 is also closely linked to the development of different types of human cancer, through its ability to enhance cancer cell migration and invasion (17). Matrix metalloproteinases (MMPs), members of the zinc-dependent endoprotease family, are important enzymes involved in degrading the dermal extracellular matrix (ECM); in particular, MMP-9 is important in cancer cell invasion and metastasis (18). In the present study, THBS4 and lncRNA-THBS4-003 expression levels are analyzed in PCa tissue in comparison with normal prostate tissue samples, and its potential biomedical functions in vitro are investigated. The aim of the study is to confirm whether lncRNA-THBS4-003 is a potential therapeutic target due to its role in PCa migration and invasion.

Materials and methods

Ethical statement

The present study was approved by the Institutional Review Board of the First Affiliated Hospital of Nanjing Medical University (Nanjing, China). During recruitment, written informed consent was obtained from all participants involved in the present study.

Tissue collection

Primary PCa and adjacent non-tumor tissue samples were collected from patients undergoing radical prostatectomy between 2011 and 2013 at the Department of Urology, the First Affiliated Hospital of Nanjing Medical University. Neither local nor systemic treatment had been administered in these patients prior to surgery. A total of 46 samples from 46 patients undergoing radical prostatectomy were collected in this study. The size of samples were 0.5cm3, at least containing 200 mg cells. Following surgery, all the samples were immediately frozen and stored in liquid nitrogen until further analysis. Only samples containing >70% tumor cells were used for the extraction of total RNA. All experiments were approved by the Research Ethics Committee of Nanjing Medical University,. Detailed information on each tissue donor is provided in Table I.
Table I

Patient characteristics.

CharacteristicNumber of PCa samples (n=46)
Age (years)
 Median (range)
T stage
 T16
 T222
 T310
 T48
N stage
 N038
 N18
M stage
 M046
 M10
Gleason score
 <713
 720
 >713

PCa, prostate cancer; T, tumor; N, node; M, metastasis.

Bioinformatics microarray data analysis

The microarray contained 8,277 lncRNA probes, which were designed by Arraystar Human LncRNA Expression Microarray (version 4.0; Arraystar, Inc., Rockville, MA, USA), based on the RefSeq (http://www.ncbi.nlm.nih.gov/refseq/), UCSC Known genes (http://genome.ucsc.edu/), and Ensembl (http://ensemblgenomes.org/)databases and associated literature (19,20); 32,207 protein-coding transcripts were used for microarray assays in three PCa tissue samples and their matched non-tumor samples. Differentially expressed lncRNAs and mRNAs, found to be statistically significant [P<0.05; fold-change (FC)>2] between the two groups were identified by comparing the normalized expression levels in the tumor and non-tumor samples using a paired t-test. Hierarchical clustering was then performed to analyze the differential lncRNA and mRNA expression patterns.

Cell lines and cell culture

The DU145 and PC-3 human PCa cell lines were purchased from the Institute of Biochemistry and Cell Biology of the Chinese Academy of Sciences (Shanghai, China). The DU145 and PC-3 cells (60-70% confluence) were cultured in F-12K (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin and 100 mg/ml streptomycin (Gibco; Thermo Fisher Scientific, Inc.) at 37°C with 5% CO2.

RNA isolation and reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis

For the analyses of mRNA, total RNA was extracted from 75 mg tissue samples and cultured cells using 1 ml TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer's protocol, and centrifugation at 12,000 × g (15 min at 4°C). For RT-qPCR, 1 µg total RNA was reverse transcribed into cDNA in a final volume of 20 µl, using random primers and a High Capacity RNA-to-cDNA kit (Applied Biosystems; Thermo Fisher Scientific, Inc.), according to the manufacturer's protocol. The RT reaction was performed at 37°C for 60 min, followed by 95°C for 5 min. The expression levels of lncRNA-THBS4-003 and THBS4 in the PCa cell lines and tissues were then measured using qPCR, according to the standard protocol of the SYBR Select Master mix (Applied Biosystems; Thermo Fisher Scientific, Inc.). The sequences of the PCR primers used were as follows: lncRNA-THBS4-003, forward 5′-ATGAAGGCTCTGAGTTGGTG-3′ and reverse 5′-CTTGGAAGTCCTCAGGGATG-3′; THBS4, forward 5′-GTTGCAGAACCTGGCATTCAG-3′ and reverse 5′-CCCTGGACCTGTCTTAGACTTCA-3′; and β-actin, forward 5′-ACTGGAACGGTGAAGGTGAC-3′ and reverse 5′-AGAGAAGTGGGGTGGCTTTT-3′. Primers were synthesized by Invitrogen (Thermo Fisher Scientific, Inc.). The mRNA detection reaction was performed under the following conditions: 50°C for 2 min, 95°C for 2 min, 40 cycles at 95°C for 15 sec, and 60°C for 1 min. The expression levels of lncRNA-THBS4-003 and THBS4 were normalized to that of β-actin and calculated using the ΔΔCq method (21). The reactions were performed and analyzed using an ABI StepOne plus system (Applied Biosystems; Thermo Fisher Scientific, Inc.). All reactions were run in triplicate.

Small interfering (si)RNA transfection

Briefly, 1×105 cells were seeded into six-well plates and cultured in complete growth media at 37°C until the cell density reached 60–70%, prior to siRNA transfection using Lipofectamine 2000 (Thermo Fisher Scientific, Inc.), according to the manufacturer's protocol. The cells were harvested after 48 h at 37°C for RT-qPCR and Western blot analyses. The sequences of the siRNAs used in the present study were as follows: 5′-GGCAACAGCUACAGUACAATT-3′ and 5′-UUGUACUGUAGCUGUUGCCTT-3′ for si-lncRNA-THBS4-003, 5′-GGCAGUUCUUGGGUCAAAUTT-3′ and 5′-AUUUGACCCAAGAACUGCCTT-3′ for si-THBS4, and 5′-UUCUCCGAACGUGUCACGUTT-3′ and 5′-ACGUGACACGUUCGGAGAATT-3′ for the control siRNA (Invitrogen; Thermo Fisher Scientific, Inc.).

Cell migration and invasion assays

For the migration assays, 3×104 cells in serum-free medium were placed in the upper chamber of a Transwell (pore size, 8 mm; BD Biosciences, San Jose, CA, USA). For the invasion assays, cells with 200 µl serum-free medium were placed in upper chambers coated with Matrigel (BD Biosciences), according to the manufacturer's protocol. Medium containing 10% FBS was immediately added to the lower chamber as a chemoattractant. Following incubation for 24 h at 37°C, the cells, which had not migrated through the pores of the Transwell inserts were manually removed using a cotton swab, and those cells on the lower surface of the membrane were fixed in 95% ethanol and stained with 0.1% crystal violet (Beyotime Institute of Biotechnology, Haimen, China). The numbers of cells in five randomly-selected fields were determined for each chamber, and the average value was calculated. Each experiment was performed in triplicate. Matrigel invasion assays were performed, as described previously (22).

Protein isolation and Western blot analysis

The tissue samples and cells were washed twice in ice-cold phosphate-buffered saline and then lysed in buffer containing 20 mM Tris-HCl (pH 7.4; Bio-Rad Laboratories, Inc., Hercules, CA, USA), 137 mM NaCl, 10% glycerol, 1% Triton X-100, 2 mM EDTA, 25 mM β-glycerophosphate, 2 mM sodium pyrophosphate and 0.5 mM dithiothreitol (all purchased from Sigma-Aldrich, St. Louis, MO, USA) with protease inhibitors at 4°C for 30 min. Subsequently, cellular debris was removed by centrifugation of the lysate at 12,000 × g for 10 min at 4°C. The supernatants (50 µl) were mixed with equal volumes of 2X sodium dodecyl sulfate (SDS) sample buffer (Sigma-Aldrich) and heated to 100°C for 10 min. An equal volume of sample was fractionated by SDS-PAGE on a 10% acrylamide gel and transferred onto polyvinylidene difluoride membranes using a Bio-Rad transfer system (version 4.62) (both purchased from Bio-Rad Laboratories, Inc.), according to the manufacturer's protocol. Following blocking of the non-specific binding sites with 5% nonfat milk in Tris-buffered saline with Tween 20, containing 50 mM Tris, 0.15 M NaCl and 0.1% Tween 20 (pH 7.6) for 1 h, the membranes were probed with THBS4 rabbit polyclonal antibody (1:2,000 dilution; cat. no. ab121094; Abcam, Cambridge, MA, USA), p38 rabbit polyclonal antibody (1:1,000 dilution; cat. no. ab7952; Abcam), rabbit polyclonal anti-MMP-9 antibody (1:1,000 dilution; cat. no. ab38898; Abcam), or β-actin rabbit antibody (1:1,000 dilution; cat. no. 8457; Cell Signaling Technology, Inc., Danvers, MA, USA) at 4°C overnight, followed by incubation with horseradish peroxidase-conjugated goat anti-rabbit secondary antibodies (1:1,000 dilution; cat. no. 7074; Cell Signaling Technology, Inc.) for 1 h at 25°C. Immunoreactive bands were visualized using enhanced chemiluminescence reagents (Thermo Fisher Scientific, Inc.), according to the manufacturer's protocol. Densitometric analysis of the immunoblots was performed using QuantityOne software (version 4.62; Bio-Rad Laboratories, Inc.). Protein levels were determined by normalization to β-actin, and the mean ± standard deviation was calculated from three individual experiments.

Statistical analysis

The results are presented as the mean ± standard error of the mean. Differences between groups were assessed for significance using Student's t-test. P<0.05 was considered to indicate a statistically significant difference. All statistical analyses were performed using SPSS 11.0 for Windows (SPSS Inc, Chicago, IL, USA).

Results

Expression of THBS4 is increased in resected PCa tissue samples

In the present study, a microarray containing 8,277 lncRNA probes and 32,207 mRNA probes was used to identify dysregulated mRNAs in three patients with PCa. Among these mRNAs, 354 were significantly upregulated and 350 were significantly downregulated (P<0.05; FC>2; Fig. 1A). The most significantly upregulated mRNA was THBS4 (P<0.05; FC>2).
Figure 1

Expression of lncRNA-THBS4-003 in PCa and adjacent non-tumor tissues. (A) A microarray containing 8,277 lncRNA probes and 32,207 mRNA probes was used to identify dysregulated mRNAs in three patients with PCa. Of these, 354 mRNAs were significantly upregulated and 350 were significantly downregulated (P<0.05; FC>2; red = high expression, green = low expression). (B) Higher expression levels of THBS4 were found in PCa tissues, compared with adjacent non-tumor tissues. (C) Protein expression levels of THBS4 in three matched non-tumor/tumor tissues were detected using Western blot analysis. (D) Quantification of western blot analysis. Data are presented as the mean ± standard deviation. *P<0.05. β-actin was used as an internal control. PCa prostate cancer; THBS4, thrombospondin 4; N, non-tumor; T, tumor.

THBS4 was selected to confirm the differential expression levels in 46 paired PCa and adjacent non-tumor tissue samples using RT-qPCR. The expression of THBS4 was significantly higher in the PCa tissues, compared with that in the adjacent non-tumor tissues (Fig. 1B). Similarly, the results of the Western blot analyses revealed that the protein expression level ofTHBS was higher in the PCa tumor tissues, compared with the adjacent non-tumor tissues collected from the same patients (Fig. 1C).

Expression of lncRNA-THBS4-003 is increased in resected PCa tissue samples

The expression of lncRNA-THBS4-003 was analyzed in 46 primary PCa and adjacent non-tumor tissue samples using RT-qPCR. The expression of lncRNA-THBS4-003 was significantly higher in the tumor tissues, compared with non-tumor tissues (Fig. 2A).
Figure 2

Expression of lncRNA-THBS4-003 in PCa and adjacent non-tumor tissues. (A) Expression levels of lncRNA-THBS4-003 were higher in the PCa tissues, compared with the adjacent non-tumor tissues. (B) Expression of lncRNA-THBS4-003 in patients with different Gleason scores. β-actin was used as a loading control. Data are presented as the mean ± standard error of the mean. *P<0.05 (determined using Student's t-test). (C) Expression levels of THBS4 and lncRNA-THBS4-003 were positively correlated in PCa tissues (P<0.0001). PCa, prostate cancer; lncRNA, long noncoding RNA; THBS4, thrombospondin 4.

In addition, patients with Gleason scores >7 exhibited higher expression levels of lncRNA-THBS4-003, compared with the patients with lower Gleason scores (Fig. 2B). Statistical analyses of the expression levels of THBS4 and lncRNA-THBS4-003 revealed a Pearson's correlation coefficient of 0.641 (P<0.0001), indicating a positive correlation between the expression levels of THBS4 and lncRNA-THBS4-003 in PCa (Fig. 2C).

Effects of THBS4 knockdown on PCa cell lines

In the present study, siRNA-mediated knockdown of THBS4 was performed in the PCa cells to investigate the effects of THBS4 on the migration and invasion of the PCa cells. The level of silencing achieved was also analyzed by performing RT-qPCR and Western blotting. The mRNA expression levels of THBS4 and lncRNA-THBS4-003 were successfully reduced in the cells transfected with si-THBS4 (Fig. 3A). Suppressing the expression of THBS4 also reduced the expression levels of p38 and MMP-9 (Fig. 3B). Furthermore, the numbers of migrated and invaded cells transfected with si-THBS4 were significantly lower, compared with the cells transfected with the control (Fig. 3C and D).
Figure 3

Effects of THBS4 knockdown on PCa cell lines. (A) Expression levels of THBS4 mRNA and lncRNA-THBS4-003 following transfection with mock, nc or si-THBS4. β-actin was used as a loading control. (B) Expression levels of THBS4, P38 and MMP-9 following transfection with mock, nc or si-THBS4. THBS4 knockdown inhibited the cell (C) migration and (D) invasion in vitro. Data are presented as the mean ± standard error of the mean of at least three independent experiments. *P<0.05. Original magnification ×200. PCa, prostate cancer; lncRNA, long noncoding RNA; THBS4, thrombospondin 4; si-THBS4, small interfering THBS4; MMP-9, matrix metallorpoteinase-9; nc, negative control.

Knockdown of lncRNA-THBS4-003 inhibits PCa cell migration and invasion in vitro

As shown in Fig. 4A, the expression levels of lncRNA-THBS4-003 in the PC-3 cells transfected with siRNA were examined. lncRNA-THBS4-003 knockdown significantly suppressed the migratory and invasive abilities of the PCa cells (Fig. 4B and C).
Figure 4

Knockdown of lncRNA-THBS4-003 inhibits PCa cell line migration and invasion in vitro. (A) Expression levels of lncRNA-THBS4-003 in transfected PC-3 cells were measured using reverse transcription-quantitative polymerase chain reaction analysis. β-actin was used as a loading control (determined using Student's t-test). lncRNA-THBS4-003 knockdown inhibited cell (B) migration and (C) invasion in vitro. Data are presented as the mean ± standard error of the mean of at least three independent experiments. *P<0.05. Original magnification ×200. PCa, prostate cancer; lncRNA, long noncoding RNA; THBS4, thrombospondin 4; si-THBS4, small interfering-THBS4, nc, negative control.

Reciprocal regulation of lncRNA-THBS4-003 and THBS4 contribute to PCa cell line migration and invasion, and regulate levels of MMP-9 through the MAPK signaling pathway

Knocking down the expression of THBS4 successfully reduced the expression of lncRNA-THBS4-003 in the cells transfected with si-THBS4 (Fig. 3A). Statistical analyses of the expression levels of THBS4 and lncRNA-THBS4-003 found a Pearson's correlation coefficient of 0.641 (P<0.0001; Fig. 2C). At 72 h post-transfection, the protein levels of THBS4, p38 and MMP-9 were significantly decreased in the cells transfected with si-lncRNA-THBS4-003, compared with the cells transfected with the control siRNA (Fig. 5).
Figure 5

Expression levels of THBS4, P38 and MMP-9 are decreased following transfection with si-lncRNA-THBS4-003. *P<0.05. lncRNA, long noncoding RNA; THBS4, thrombospondin 4; si-THBS4, small interfering-THBS4; MMP-9, matrix metallorpoteinase-9; nc, negative control.

Discussion

The present study is the first, to the best our out knowledge, to report lncRNA-THBS4-003 as a potentially useful biomarker for disease progression in patients with PCa. In the present study, a microarray containing 8,277 lncRNA probes and 32,207 mRNA probes was used to identify dysregulated mRNAs in three patients with PCa. A total of 354 mRNAs were found to be significantly upregulated and 350 were downregulated (P<0.05; FC>2). The most significantly upregulated mRNA was THBS4 (P<0.05; FC>2). lncRNA-THBS4-003 is located at chromosome 5p14.1 and partially overlaps the protein-coding gene, THBS4. Western blot and RT-qPCR analyses revealed that lncRNA-THBS4-003 and the expression levels of THBS4 were higher in tumor tissues, compared with the adjacent non-tumor tissues collected from the same patients. Statistical analyses of THBS4 and lncRNA-THBS4-003 demonstrated a Pearson's correlation coefficient of 0.641 (P<0.0001). The expression level of lncRNA-THBS4-003 was significantly higher, compared with the adjacent non-tumor tissues. Patients with Gleason scores >7 exhibited higher expression levels of lncRNA-THBS4-003, compared with those with lower scores. The aberrant expression and function of lncRNA-THBS4-003 in PCa remain to be elucidated. Using cell migration and invasion assays to evaluate migratory and invasive responses, lncRNA-THBS4-003 knockdown was found to significantly decrease the migratory and invasive abilities of the PCa cells in vitro, and to inhibit the expression levels of THBS4, p38 and MMP-9. The thrombospondins (THBSs) are a family of five extracellular calcium-binding proteins (THBS1, THBS2, THBS3, THBS4 and THBS5/COMP), which are important in diverse processes through their interactions with the ECM. THBS4 is involved in several critical processes, including cellular proliferation, attachment, adhesion and migration, cytoskeletal organization, cell-to-cell interactions, and the promotion of neurite outgrowth (23–26). The role of THBS4 in cancer is well understood, and increasing evidence suggests that THBS4 is involved in colorectal, gastric and prostate carcinomas. THBS4 is reported to be expressed at high levels by cancer-associated fibroblasts as a constituent of desmoplastic stroma in prostate and gastric cancer (20,27–30). Previous reports have shown that THBS4-induced activation of p38-MAPK regulates vascular inflammation and atherogenesis (20,31,32). It is known that p38 MAPK is capable of regulating several cellular responses to cytokines and stress; however, studies have demonstrated that p38 is also closely associated with the development of different types of human cancer through its ability to elevate cancer cell migration and invasion in response to various stimuli, including inflammatory factors (31). Evidence has shown that p38 MAPK signals are involved in downregulating the expression of MMP-9, which has been linked to tumor migration and invasion (32). The present study demonstrated significant downregulation in the protein levels of p38 and MMP-9 following the suppression of lncRNA-THBS4-003 or THBS4. The numbers of migrated and invaded cells transfected with si-lncRNA-THBS4-003 or si-THBS4 were also significantly lower, compared with the cells transfected with control siRNA. The present study revealed that the forced knockdown of lncRNA-THBS4-003 or THBS4 decreased the in vitro migratory and invasive abilities of PCa cells through the MAPK signaling pathway. THBS4 is an adhesive glycoprotein that mediates cell-to-cell and cell-to-matrix interactions and is involved in the regulation of vascular inflammation. THBS4 and lncRNA-THBS4-003 can promote angiogenesis in prostate tissue (33). In the present study, p38 and MMP-9 were decreased following knockdown of THBS4 and lncRNA-THBS4-003 in prostate cancer cell lines. MMP-9 can promote angiogenesis, tumor migration and invasion in prostate cancer. In conclusion, the present study demonstrates that THBS4 and lncRNA-THBS4-003 serve a significant role in PCa proliferation and migration via the MMP-9 and p38 MAPK signaling pathway.
  32 in total

1.  Uncovering the role of genomic "dark matter" in human disease.

Authors:  Lance Martin; Howard Y Chang
Journal:  J Clin Invest       Date:  2012-05-01       Impact factor: 14.808

2.  Regulation of apoptosis by a prostate-specific and prostate cancer-associated noncoding gene, PCGEM1.

Authors:  Xiaoqin Fu; Lakshmi Ravindranath; Nicholas Tran; Gyorgy Petrovics; Shiv Srivastava
Journal:  DNA Cell Biol       Date:  2006-03       Impact factor: 3.311

Review 3.  Matrix metalloproteinases: a review.

Authors:  H Birkedal-Hansen; W G Moore; M K Bodden; L J Windsor; B Birkedal-Hansen; A DeCarlo; J A Engler
Journal:  Crit Rev Oral Biol Med       Date:  1993

4.  Thrombospondin-4 regulates vascular inflammation and atherogenesis.

Authors:  Ella G Frolova; Elzbieta Pluskota; Irene Krukovets; Tim Burke; Carla Drumm; Jonathan D Smith; Lauren Blech; Maria Febbraio; Paul Bornstein; Edward F Plow; Olga I Stenina
Journal:  Circ Res       Date:  2010-09-30       Impact factor: 17.367

5.  Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project.

Authors:  Ewan Birney; John A Stamatoyannopoulos; Anindya Dutta; Roderic Guigó; Thomas R Gingeras; Elliott H Margulies; Zhiping Weng; Michael Snyder; Emmanouil T Dermitzakis; Robert E Thurman; Michael S Kuehn; Christopher M Taylor; Shane Neph; Christoph M Koch; Saurabh Asthana; Ankit Malhotra; Ivan Adzhubei; Jason A Greenbaum; Robert M Andrews; Paul Flicek; Patrick J Boyle; Hua Cao; Nigel P Carter; Gayle K Clelland; Sean Davis; Nathan Day; Pawandeep Dhami; Shane C Dillon; Michael O Dorschner; Heike Fiegler; Paul G Giresi; Jeff Goldy; Michael Hawrylycz; Andrew Haydock; Richard Humbert; Keith D James; Brett E Johnson; Ericka M Johnson; Tristan T Frum; Elizabeth R Rosenzweig; Neerja Karnani; Kirsten Lee; Gregory C Lefebvre; Patrick A Navas; Fidencio Neri; Stephen C J Parker; Peter J Sabo; Richard Sandstrom; Anthony Shafer; David Vetrie; Molly Weaver; Sarah Wilcox; Man Yu; Francis S Collins; Job Dekker; Jason D Lieb; Thomas D Tullius; Gregory E Crawford; Shamil Sunyaev; William S Noble; Ian Dunham; France Denoeud; Alexandre Reymond; Philipp Kapranov; Joel Rozowsky; Deyou Zheng; Robert Castelo; Adam Frankish; Jennifer Harrow; Srinka Ghosh; Albin Sandelin; Ivo L Hofacker; Robert Baertsch; Damian Keefe; Sujit Dike; Jill Cheng; Heather A Hirsch; Edward A Sekinger; Julien Lagarde; Josep F Abril; Atif Shahab; Christoph Flamm; Claudia Fried; Jörg Hackermüller; Jana Hertel; Manja Lindemeyer; Kristin Missal; Andrea Tanzer; Stefan Washietl; Jan Korbel; Olof Emanuelsson; Jakob S Pedersen; Nancy Holroyd; Ruth Taylor; David Swarbreck; Nicholas Matthews; Mark C Dickson; Daryl J Thomas; Matthew T Weirauch; James Gilbert; Jorg Drenkow; Ian Bell; XiaoDong Zhao; K G Srinivasan; Wing-Kin Sung; Hong Sain Ooi; Kuo Ping Chiu; Sylvain Foissac; Tyler Alioto; Michael Brent; Lior Pachter; Michael L Tress; Alfonso Valencia; Siew Woh Choo; Chiou Yu Choo; Catherine Ucla; Caroline Manzano; Carine Wyss; Evelyn Cheung; Taane G Clark; James B Brown; Madhavan Ganesh; Sandeep Patel; Hari Tammana; Jacqueline Chrast; Charlotte N Henrichsen; Chikatoshi Kai; Jun Kawai; Ugrappa Nagalakshmi; Jiaqian Wu; Zheng Lian; Jin Lian; Peter Newburger; Xueqing Zhang; Peter Bickel; John S Mattick; Piero Carninci; Yoshihide Hayashizaki; Sherman Weissman; Tim Hubbard; Richard M Myers; Jane Rogers; Peter F Stadler; Todd M Lowe; Chia-Lin Wei; Yijun Ruan; Kevin Struhl; Mark Gerstein; Stylianos E Antonarakis; Yutao Fu; Eric D Green; Ulaş Karaöz; Adam Siepel; James Taylor; Laura A Liefer; Kris A Wetterstrand; Peter J Good; Elise A Feingold; Mark S Guyer; Gregory M Cooper; George Asimenos; Colin N Dewey; Minmei Hou; Sergey Nikolaev; Juan I Montoya-Burgos; Ari Löytynoja; Simon Whelan; Fabio Pardi; Tim Massingham; Haiyan Huang; Nancy R Zhang; Ian Holmes; James C Mullikin; Abel Ureta-Vidal; Benedict Paten; Michael Seringhaus; Deanna Church; Kate Rosenbloom; W James Kent; Eric A Stone; Serafim Batzoglou; Nick Goldman; Ross C Hardison; David Haussler; Webb Miller; Arend Sidow; Nathan D Trinklein; Zhengdong D Zhang; Leah Barrera; Rhona Stuart; David C King; Adam Ameur; Stefan Enroth; Mark C Bieda; Jonghwan Kim; Akshay A Bhinge; Nan Jiang; Jun Liu; Fei Yao; Vinsensius B Vega; Charlie W H Lee; Patrick Ng; Atif Shahab; Annie Yang; Zarmik Moqtaderi; Zhou Zhu; Xiaoqin Xu; Sharon Squazzo; Matthew J Oberley; David Inman; Michael A Singer; Todd A Richmond; Kyle J Munn; Alvaro Rada-Iglesias; Ola Wallerman; Jan Komorowski; Joanna C Fowler; Phillippe Couttet; Alexander W Bruce; Oliver M Dovey; Peter D Ellis; Cordelia F Langford; David A Nix; Ghia Euskirchen; Stephen Hartman; Alexander E Urban; Peter Kraus; Sara Van Calcar; Nate Heintzman; Tae Hoon Kim; Kun Wang; Chunxu Qu; Gary Hon; Rosa Luna; Christopher K Glass; M Geoff Rosenfeld; Shelley Force Aldred; Sara J Cooper; Anason Halees; Jane M Lin; Hennady P Shulha; Xiaoling Zhang; Mousheng Xu; Jaafar N S Haidar; Yong Yu; Yijun Ruan; Vishwanath R Iyer; Roland D Green; Claes Wadelius; Peggy J Farnham; Bing Ren; Rachel A Harte; Angie S Hinrichs; Heather Trumbower; Hiram Clawson; Jennifer Hillman-Jackson; Ann S Zweig; Kayla Smith; Archana Thakkapallayil; Galt Barber; Robert M Kuhn; Donna Karolchik; Lluis Armengol; Christine P Bird; Paul I W de Bakker; Andrew D Kern; Nuria Lopez-Bigas; Joel D Martin; Barbara E Stranger; Abigail Woodroffe; Eugene Davydov; Antigone Dimas; Eduardo Eyras; Ingileif B Hallgrímsdóttir; Julian Huppert; Michael C Zody; Gonçalo R Abecasis; Xavier Estivill; Gerard G Bouffard; Xiaobin Guan; Nancy F Hansen; Jacquelyn R Idol; Valerie V B Maduro; Baishali Maskeri; Jennifer C McDowell; Morgan Park; Pamela J Thomas; Alice C Young; Robert W Blakesley; Donna M Muzny; Erica Sodergren; David A Wheeler; Kim C Worley; Huaiyang Jiang; George M Weinstock; Richard A Gibbs; Tina Graves; Robert Fulton; Elaine R Mardis; Richard K Wilson; Michele Clamp; James Cuff; Sante Gnerre; David B Jaffe; Jean L Chang; Kerstin Lindblad-Toh; Eric S Lander; Maxim Koriabine; Mikhail Nefedov; Kazutoyo Osoegawa; Yuko Yoshinaga; Baoli Zhu; Pieter J de Jong
Journal:  Nature       Date:  2007-06-14       Impact factor: 49.962

6.  Thrombospondin-4 is a putative tumour-suppressor gene in colorectal cancer that exhibits age-related methylation.

Authors:  Sonia A Greco; June Chia; Kelly J Inglis; Sarah-Jane Cozzi; Ingunn Ramsnes; Ronald L Buttenshaw; Kevin J Spring; Glen M Boyle; Daniel L Worthley; Barbara A Leggett; Vicki L J Whitehall
Journal:  BMC Cancer       Date:  2010-09-16       Impact factor: 4.430

7.  Global gene expression analysis of reactive stroma in prostate cancer.

Authors:  Olga Dakhova; Mustafa Ozen; Chad J Creighton; Rile Li; Gustavo Ayala; David Rowley; Michael Ittmann
Journal:  Clin Cancer Res       Date:  2009-06-09       Impact factor: 12.531

8.  The majority of total nuclear-encoded non-ribosomal RNA in a human cell is 'dark matter' un-annotated RNA.

Authors:  Philipp Kapranov; Georges St Laurent; Tal Raz; Fatih Ozsolak; C Patrick Reynolds; Poul H B Sorensen; Gregory Reaman; Patrice Milos; Robert J Arceci; John F Thompson; Timothy J Triche
Journal:  BMC Biol       Date:  2010-12-21       Impact factor: 7.431

9.  Dissecting Major Signaling Pathways throughout the Development of Prostate Cancer.

Authors:  Henrique B da Silva; Eduardo P Amaral; Eduardo L Nolasco; Nathalia C de Victo; Rodrigo Atique; Carina C Jank; Valesca Anschau; Luiz F Zerbini; Ricardo G Correa
Journal:  Prostate Cancer       Date:  2013-04-29

10.  Thrombospondin-4 controls matrix assembly during development and repair of myotendinous junctions.

Authors:  Arul Subramanian; Thomas F Schilling
Journal:  Elife       Date:  2014-06-18       Impact factor: 8.140

View more
  12 in total

Review 1.  Thrombospondin-4 in tissue remodeling.

Authors:  Olga Stenina-Adognravi; Edward F Plow
Journal:  Matrix Biol       Date:  2017-11-11       Impact factor: 11.583

2.  Thrombospondin-4 Promotes Neuronal Differentiation of NG2 Cells via the ERK/MAPK Pathway.

Authors:  Hai Jie Yang; Shuang Ping Ma; Fei Ju; Ya Ping Zhang; Zhi Chao Li; Bin Bin Zhang; Jun Jiang Lian; Lei Wang; Bin Feng Cheng; Mian Wang; Zhi Wei Feng
Journal:  J Mol Neurosci       Date:  2016-09-19       Impact factor: 3.444

Review 3.  Signaling Pathways and Targeted Therapies for Stem Cells in Prostate Cancer.

Authors:  Madhuvanthi Giridharan; Vasu Rupani; Satarupa Banerjee
Journal:  ACS Pharmacol Transl Sci       Date:  2022-03-30

Review 4.  Long non-coding RNAs in genitourinary malignancies: a whole new world.

Authors:  Ronan Flippot; Guillaume Beinse; Alice Boilève; Julien Vibert; Gabriel G Malouf
Journal:  Nat Rev Urol       Date:  2019-08       Impact factor: 14.432

5.  Over-expression of Thrombospondin 4 correlates with loss of miR-142 and contributes to migration and vascular invasion of advanced hepatocellular carcinoma.

Authors:  Fang Su; Jun Zhao; Shukui Qin; Rui Wang; Yumei Li; Qiang Wang; Yi Tan; Hao Jin; Fangquan Zhu; Yurong Ou; Zenong Cheng; Wen Su; Fuyou Zhao; Yan Yang; Zhengguang Zhou; Jiyue Zheng; Yawei Li; Zhongwen Li; Qiong Wu
Journal:  Oncotarget       Date:  2017-04-04

6.  TRIM36, a novel androgen-responsive gene, enhances anti-androgen efficacy against prostate cancer by inhibiting MAPK/ERK signaling pathways.

Authors:  Chao Liang; Shangqian Wang; Chao Qin; Meilin Bao; Gong Cheng; Bianjiang Liu; Pengfei Shao; Qiang Lv; Ninghong Song; Lixin Hua; Min Gu; Jie Li; Zengjun Wang
Journal:  Cell Death Dis       Date:  2018-02-05       Impact factor: 9.685

7.  Identification of candidate genes in ischemic cardiomyopathy by gene expression omnibus database.

Authors:  Haiming Dang; Yicong Ye; Xiliang Zhao; Yong Zeng
Journal:  BMC Cardiovasc Disord       Date:  2020-07-06       Impact factor: 2.298

8.  The clinicopathological significance of Thrombospondin-4 expression in the tumor microenvironment of gastric cancer.

Authors:  Kenji Kuroda; Masakazu Yashiro; Tomohiro Sera; Yurie Yamamoto; Yukako Kushitani; Atsushi Sugimoto; Syuhei Kushiyama; Sadaaki Nishimura; Shingo Togano; Tomohisa Okuno; Tatsuro Tamura; Takahiro Toyokawa; Hiroaki Tanaka; Kazuya Muguruma; Masaichi Ohira
Journal:  PLoS One       Date:  2019-11-08       Impact factor: 3.240

9.  DNA Methylation in INA, NHLH2, and THBS4 Is Associated with Metastatic Disease in Renal Cell Carcinoma.

Authors:  Olga Katzendorn; Inga Peters; Natalia Dubrowinskaja; Joana M Moog; Christel Reese; Hossein Tezval; Pouriya Faraj Tabrizi; Jörg Hennenlotter; Marcel Lafos; Markus A Kuczyk; Jürgen Serth
Journal:  Cancers (Basel)       Date:  2021-12-22       Impact factor: 6.639

10.  Screening key miRNAs and genes in prostate cancer by microarray analysis.

Authors:  Jianhui Wu; Xuemei Li; Fei Luo; Jun Yan; Kuo Yang
Journal:  Transl Cancer Res       Date:  2020-02       Impact factor: 1.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.